INTRODUCTION
Lymphocyte depletion of lymphoid tissues (1), peripheral lymphopenia (2) , and both in vivo (2, 3) and in Preliminary reports on this work were published: 1973. Proc. Leucocyte Cult. Conf. 7: 627-642, and 1973. J. Natl. Cancer Inst. 51: 345-351 .
Received for publication 10 February 1975 and in revised form 14 April 1975. vitro (4) (5) (6) (7) (8) (9) impairment of immune responses may occur with Hodgkin's disease. This acquired immunodeficiency primarily affects cell-mediated immunity (10, 11) and is associated with increased susceptibility to infections (12) and accelerated tumor expansion (2) .
A number of mechanisms could contribute to the immunodeficiency with Hodgkin's disease: (a) Direct involvement of immunoreactive cells in the neoplastic process could result in their functional impairment (13) or critical restriction in the range of their responses (14) . (b) A deficiency of immunobiologically active substances, (e.g. thymic products) which are needed to sustain (15) as well as to develop immune competence, could lead to lymphocyte depletion. (c) An excess of suppressor cells or of their functional impact (16, 17) relative to effector cells could inhibit immune responses. (d) Occasionally, plasma from patients with Hodgkin's disease contains lymphocytotoxic antibody (18) or otherwise inhibits lymphoproliferative responses (19) .
This laboratory has reported that irradiated leukocytes from some patients with Hodgkin's disease do not stimulate normal responses in the mixed leukocyte cul-this abnormality is probably caused by suppression of the response by patient leukocytes.
METHODS
Subjects. A histologic diagnosis was made on each patient with Hodgkin's disease or lymphocytic lymphoma. Hodgkin's disease was classified histologically (1) and staged clinically (24) with lymphangiography and laparotomy performed on selected patients. Patients with lymphocytic lymphoma had no light microscopic evidence of blood or bone marrow involvement. Chronic lymphocytic leukemia was diagnosed by an absolute lymphocyte count > 18,000 per mm8 of blood with lymphocytes comprising t 30%o of cells in bone marrow aspirates. Between 10 and 15% of circulating lymphoid cells from the patient with the Sezary syndrome had the morphology of Sezary cells. Immunologically normal blood was obtained from healthy volunteers or patients awaiting elective surgery (e.g. herniorraphy) or convalescing from myocardial infarction. Henceforth, these are referred to as normal subjects and their cells as normal cells. Since a decline in MLR reactivity has not been observed in our culture system through the ninth age decade, no attempt was made to agematch patient and normal test subjects. Definitions. (a) Cell preparations: Leukocytes included all white blood cells harvested with leukocyte-rich plasma.
Mononuclear leukocytes (MNL) included lymphocytes, monocytes, and <.5% granulocytes; these cells were separated from whole blood by floatation. (27) .
Enzymatic pretreatments of MNL. In preliminary experiments, 4-5 X 106 MNL from normal subjects were incubated for 15 min with 0.1-0.3 U of neuraminidase (Calbiochem, San Diego, Calif.) (28) or with 500-1,500 /g of protease (Sigma Chemical Co.) (29) T and B cell identification. These tests were done on MNL preparations. T cells were identified by rosette formation with neuraminidase-pretreated sheep erythrocytes at 4CC (33) . B cells were identified by the presence of surface immunoglobulin using an immunofluorescence technique (34) and polyvalent antiserum to human immunoglobulins (Meloy Laboratories Inc., Springfield, Va.).
Serologic tissue typing. We tested for 26 HL-A and workshop specificities by the microcytotoxicity test (35) using antisera obtained from the National Institutes of Health tissue typing bank plus well-defined antisera characterized locally or obtained by donation from other investigators.
Statistical analysis. The Wilcoxon rank sum test and the x' test were used to determine the significance of differences in results between paired sets of data.
RESULTS

Survey of MLR stimulation. MLR stimulation tests
were performed on 30 patients with Hodgkin's disease, 17 with chronic lymphocytic leukemia, 13 with lymphocytic lymphoma, and 1 with the Sezary syndrome. The lowest result recorded in 50 control experiments using the microtiter plate culture system (group A) and in 50 other control experiments using the petri dish culture system (32) (group B) are listed in Table I (Fig. 1A) . In contrast, the lesser number of target cells from seven other patients with more extensive Hodgkin's disease stimulated significantly brisker MLR responses than did the higher number of target cells (P < 0.01); this is reflected in higher stimulation ratios (Fig. 1B,  closed triangles) . Most group B patients were retested after their clinical conditions had improved with chemotherapy; stimulation ratios were then at or closer to the normal range (Fig. 1B, open triangles) .
MLR suppression by patient cells. (27, 30) were applied to MNL from selected patients with Hodgkin's disease, subsequent MLR stimulation by these cells was greatly increased. The inhibiting cells were probably lymphocytes since removal of phagocytic cells did not increase low MLR stimulation. This mechanism for MLR suppression differs from that previously reported with Hodgkin's disease (19) and with systemic lupus erythematosis (37) in that patient plasma supported normal MLR responses in the present study. Suppression of MLR responses with systemic lupus erythematosis appears to be caused by circulating antibody to components of (probably responder) T-cell membranes. The MLR suppression that is the subject of the present report appears to be related to the actual presence of patient lymphocytes.
It is known that a polymorphonuclear leukocytosis suppresses delayed hypersensitivity in vivo (38) and an excess of granulocytes inhibits the MLR in vitro (36) (10, 11) . Conversely, cell-mediated immunity is less severely impaired than humoral immunity with common variable immunoglobulin deficiency (43 An overall relationship was demonstrated between subnormal MLR activation and responsiveness by MNL from patients with advanced Hodgkin's disease. Maximum responses by patient lymphocytes was only achieved with high numbers of normal target cells which is compatible with Hodgkin's disease having a particularly adverse effect upon effector T cells as are other manifestations of cell-mediated immune impairment (2-11). The fact that humoral immunity is rarely deficient with Hodgkin's disease (10, 11) suggests that helper T cells as well as the B-cell series are not severely depleted in these patients. The present study suggests that suppressor lymphocytes are not depleted and may be present in excessive concentrations. This suppression and deficit of effector T cells may be further compounded by suppression of immune responses by granulocytes.
Chronic lymphocytic leukemia and lymphocytic lymphoma are predominantly B-cell neoplasms (49) (50) (51) . Current evidence suggests that suppressor lymphocytes are predominately T cells (16, 41, 52, 53) . It is therefore not surprising that subnormal MLR stimulation was not observed in the present study on any of 30 patients with chronic lymphocytic leukemia or lymphocytic lymphoma where according to published experience (49-51) the majority of neoplasms are of the B-cell series.
At present there is no method available for identifying and quantitating suppressor T cells. The in vitro method described by Waldmann et al. (41) is useful for measuring suppressor T-cell activity upon humoral immune responses. The techniques used in the present study permit functional studies on suppressor T cells in a response that is predominantly by effector T cells (47) . Both procedures offer the advantage of measuring responses by healthy immunocytes which are unaffected by disease processes under evaluation.
